Indication intelligence, analysis and sector perception

Mixed open expected; RegMed, investors should be apprehensive

February 18, 2016 6:26am

… After the stem, cell and gene therapy regenerative medicine sector stocks logged their first three-day rally since December.

If you are not listening now, you might not hear the music, and if you don't hear the music, how can you expect to find a chair when the music stops?

Subscribe … http://www.regmedinvestors.com/create-account

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, which and what of it …

DOW futures and NASDAQ futures are UP +0.4%.

U.S. stock index futures indicated a mixed open on Thursday as traders eyed oil and continued to digest the release of minutes from the Federal Reserve's last meeting.

European markets dropped into negative territory after a positive open as investors trod cautiously after a positive week so far for stocks.

Asian markets tacked on gains despite mostly poor economic data, although Chinese markets fell behind their region peers.

Data docket: initial claims and the Philly Fed Survey come out at 8:30 a.m. ET, with leading indicators due at 10:00 a.m.

The stem, cell and gene therapy RegMed sector closed POSITIVE on Wednesday, Tuesday and Friday following a NEGATIVE close on last Thursday.

Past five (5) days (of 43 covered companies):

· Wednesday closed POSITIVE with 3 decliners, 37 advancers and 3 flats;

· Tuesday closed POSITIVE with 6 decliners, 36 advancers and 1 flat;

· Monday was a holiday;

· Friday closed POSITIVE with 11 decliners, 28 advancers and 4 flats

· Last, Thursday closed NEGATIVE with 22 decliners, 17 advancers and 4 flats

An old Wall Street saying is that a rising tide lifts all boats, but no matter which way the market is moving, there are stocks that will always go their own way.

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector closed UP again – the third day with striking moves!

Unfortunately, there are more sector “participants” at risk of underperforming – it’s still all about the constant struggle between being oversold versus overbought, cash positions and “runways” – the broken record “screeches” on!

Timing is everything but the past three trading days have been the best three day stretch stocks since late-September turned into early-October.

However, let's not count our chickens before they're … sold.

MY view is there is no other interpretation than to assume the trend remains to the downside.

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you - what are today’s trades?

I am still a fence sitter on Thursday’s sector’s direction; let it play-out here are a few with aftermarket indications:

Athersys (ATHX) closed UP +$0.11 to $1.45 and has an aftermarket indication of +$0.35 after reporting 1 year results from P2 stroke study of MultiStem Cell Therapy within 36 hours to treat patients who have suffered an ischemic stroke – BUY;

bluebird bio (BLUE) closed UP +$4.11 to $54.24 and has an aftermarket indication of +$0.37 – BUY;

Capricor (CAPR) closed UP +$0.12 to $2.36 on small volume. Remember 1/19/16’s $2.03, what’s keeping it up as NO news has been attributed to this equity after a failed offering that will re-start as soon as another banker can “flog” the “hedgies” – SELL;

Intrexon (XON) closed UP +$1.72 to $32.32 and has an aftermarket indication of +0.12 - BUY;

Juno therapeutics (JUNO) closed UP +$2.30 to $34.44 and has an aftermarket indication of +$0.16. The stock is down 27% year-to-date compared to the iShares Nasdaq Biotechnology exchange-traded fund falling 24% – BUY;

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.